Targeting P2Y<sub>14</sub>R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38453952.
- Also identified by DOI 10.1038/s41467-024-46365-x and PMC identifier 10920779.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Purinergic signaling plays a causal role in the pathogenesis of inflammatory bowel disease. Among purinoceptors, only P2Y<sub>14</sub>R is positively correlated with inflammatory score in mucosal biopsies of ulcerative colitis patients, nevertheless, the role of P2Y<sub>14</sub>R in ulcerative colitis remains unclear. Here, based on the over-expressions of P2Y<sub>14</sub>R in the intestinal epithelium of mice with experimental colitis, we find that male mice lacking P2Y<sub>14</sub>R in intestinal epithelial cells exhibit less intestinal injury induced by dextran sulfate sodium. Mechanistically, P2Y<sub>14</sub>R deletion limits the transcriptional activity of cAMP-response element binding protein through cAMP/PKA axis, which binds to the promoter of Ripk1, inhibiting necroptosis of intestinal epithelial cells. Furthermore, we design a hierarchical strategy combining virtual screening and chemical optimization to develop a P2Y<sub>14</sub>R antagonist HDL-16, which exhibits remarkable anti-colitis effects. Summarily, our study elucidates a previously unknown mechanism whereby P2Y<sub>14</sub>R participates in ulcerative colitis, providing a promising therapeutic target for inflammatory bowel disease.
Medical subject headings
- Colitis, Ulcerative
- Colitis
- Inflammatory Bowel Diseases